The U.S. Food and Drug Administration has approved the use of a skin drug ‘Dupixent’ for patients aged 12 to 17 years of age.
Dupixent is a prescription drug used for treating moderate-to-severe atopic dermatitis (eczema). It is used for patients when prescription therapies are not advised by the doctor.
Atopic dermatitis is an itchy inflammation of the skin. It causes rashes, itching, swelling, cracking, dryness, and redness of the skin.
Dupixent is manufactured by Regeneron Pharmaceuticals Inc and Sanofi. FDA approved Dupixent for use in adults in 2017. However, the use of this drug in adolescents was not approved by the FDA up until now.
FDA has also approved the use of Dupixent to treat moderate-to-severe asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines.
There were clinical trials which were conducted to study the effects of using Dupixent on adolescents. During the phase 3 clinical trial, Dupixent showed results which indicated a reduction in the severity of disease and itching that helped adolescents get clearer skin.
Dupixent comes in two doses. One is 200mg and the other is 300 mg. Each of these is available as a pre-filled syringe. Dupixent is intended for injection under the skin. The injection is given every second week.
The injection should only be given at a health clinic or under guidance by a health care provider. There are also certain guidelines set by the FDA for the use of this drug.
The FDA specifies that this injection should not be injected on your own until you have been shown by your health care provider as to exactly how and where it is to be injected on your skin.
It is also adviced that the use of Dupixent should not be considered if the patient is suffering from an eye problem or is scheduled for receiving any vaccinations. It is also advised to consult your health care provider if you are pregnant, or are breastfeeding.
People suffering from atopic dermatitis is increasing over the years. Every year hundreds of new cases are reported. In India, atopic dermatitis is found in 5-15% of school children and 2-10% of adults.
According to the National Eczema Association, atopic dermatitis in US is found in 7.2% of adults and about 13% of children under the age of 18 years.
With the rise in the number of cases, the approval of Dupixent signifies an important growth for patients suffering from atopic dermatitis.